| 摘要 |
Disclosed is the use of an antibody, or antigen-binding portion thereof, which is capable of binding to the p40 subunit of IL-12 and/or IL-23, for the manufacture of a medicament in treating psoriasis in a subject by administering a first dose amount of about 180 mg to about 220 mg of the antibody, or antigen-binding portion thereof, to the subject at weeks 0 and 4, and administering a second dose amount of about 80 mg to about 120 mg of the antibody, or antigen-binding portion thereof, to the subject every 4 weeks thereafter. |
